17 - 20 february 2014 frankfurt, germany - cipf · 17th - 20th february 2014 frankfurt, germany...

17th - 20th February 2014 Frankfurt, Germany

Select your lead candidate with confidence

Improve preclinical predictability

Maximise clinical efficacy

Yet another ‘grand slam’ of a conference.

Our Partners:


COME AND JOIN US, HERE’S WHY:

Get your ADC into the clinic faster and with less riskWith the field growing ever more competitive, the pressure is on to get into Phase 1 and deliver efficacy without any slip ups. Despite rapid advances, selecting the right combinations of antibody, payload and linker is still immensely challenging and difficult to validate prior to studies in man.

Focused on resolving this issue World ADC Frankfurt 2014 will bring fresh insights and unpublished data, helping speed progress in your ADC programmes in three key areas:

Increase confidence in your candidate selection and progression by understanding how Roche, Takeda & JnJ are optimising the different ADC elements in each target indication

Improve preclinical predictability and ultimately translation by learning about the new models, assays and mechanistic studies that Pfizer, ImmunoGen & Genmab are performing successfully

Maximise the potential for clinical benefit by listening to how Agensys, Seattle Genetics & Genentech have enhanced therapeutic windows through both greater efficacy but also better tolerability

This year, to get to the heart of what was truly impeding faster progress we initiated a series of dedicated ADC brainstorming sessions.

Tapping into the experiences of 30 of the industry’s leading minds we uncovered the unspoken fears and perpetual headaches that are still lurking beneath the surface.

We’ve scoured the globe for the finest topic experts to tackle these looming obstacles and the result is our best agenda ever.

Join us this year to hear 48 expert speakers share a dazzling set of case studies that will provide a tangible impact to every one of your ADC programmes.

World ADC Frankfurt working with you

WORLD ADC FRANKFURT FEBRUARY 20142 www.adcsummit-europe.com

DAVID STOVER AGENSYS

PATRICK VINCENT TAKEDA PHARMACEUTICALS

PETER SENTER SEATTLE GENETICS

LAST YEAR’S ATTENDEES SAID:


World ADC Frankfurt: Networking within the CommunityWorld ADC Frankfurt is the definitive gathering for ADC experts in Europe. Assembling research and development groups from across pharma, biotech and academia this is the premier opportunity to discover what’s happening at the heart of the ADC field.

Our famed and unique Speed Networking session is set up specifically to connect you with new contacts and is without a doubt one of the most beneficial parts of the conference. In just 1 hour you’ll meet at least 75 ADC enthusiasts and be able to schedule all of your follow up meetings before lunch on day 1.

Leave this whirlwind session with a stack of business cards, a little out of breath and a smile on your face.

KEY BENEFITS OF ATTENDING:

Speaker Highlights

David Stover is drawing on his extensive background at Agensys to contribute to a plenary panel session focused on selection criteria for target, payload, linker and carrier specificity

Patrick Vincent will reveal how Takeda are identifying and validating the next generation of successful ADC targets and share some of their experimental project work

Peter Senter’s keynote will highlight the remarkable new developments from within Seattle Genetics including an update on their site specific PBD conjugate which has recently entered the clinic

Great conference where all the key ADC players are present. Good talks and networking with other people working on ADCs.

Great selection of speakers, very interesting meeting and great diversity

Site and organisation was perfect. Very interesting talks on the preclinic

Great event, will come back!

Speed Networking is very, very valuable…and fun!

Industry Breakdown 2013

32% Biotech

27% Pharma

23% Solution Provider

15% Academic

3% Other



SPEAKERS

48 Expert SpeakersPeter Bach BioPharmaLogic

George BadescuPolyTherics

Alain BeckPierre Fabre

Nia BeckleyGenentech

Iwan BertholjottiLonza

Goncalo BernardesCambridge University

Stefan BrachtBayer

David BramhillBramhill Consulting

Ulrich BrinkmannRoche

Ravi ChariImmunoGen

Stephane CornenSanofi

Carmen CuevasPharmaMar

Patrizio GiacominiIstituto Nazionale Tumori

Shalom GoldbergJohnson & Johnson

Anna GrabowskaUniversity of Nottingham

Nahor Haddish-BerhanePfizer

Thomas HaederBiotest

Annemarie HoneggerUniversity of Zurich

Pernille Høyrup HemmingsenGenmab

Rebecca KristeleitUCL

John LambertImmunoGen

Melissa Lapierre-DevlinTakeda Boston

Chris LeamonEndocyte

Chris LloydMedImmune

Dale LudwigEli Lilly

Alexey LugovskoyMerrimack

Andreas MadernaPfizer

Laura Melendez-AlafortUniversity of Padua

Thi-Sau MigoneIgenica

Dario NeriETH Zurich

Gerhard NiederfellnerRoche

Fredrik OlssonGenovis

Franck PavanPierre Fabre

Gillian PayneImmunoGen

Gail PhillipsGenentech

Sarah PogueTeva

David RabukaRedwood Bioscience

Ed ReillyAbbvie

David SatijnGenmab

Jonas SchaeferUniversity of Zurich

Christof SeidlTechnische Universität München

Peter SenterSeattle Genetics

David StoverAgensys/Astellas

Andrew TheobaldGSK

Floris van DelftSynaffix

Patrick VincentTakeda San Diego

Cynthia WoogeSAFC

Herren WuMedImmune



PLENARY SESSION: PIONEERING DEVELOPMENTS IN THE ANTIBODY-DRUG CONJUGATE FIELD

DISCOVERY STREAM: OPTIMISING LINKER AND DRUG COMPATIBILITY

DEVELOPMENT STREAM: IMPROVING PREDICTABILITY OF PRECLINICAL DEVELOPMENT

8.30 Innovations in ADC technology: Preclinical & clinical developments at Seattle Genetics• Novel methods for generating ADCs with high levels of homogeneity • Design of new linkers with improved stability profiles• Demonstrating effectiveness of ADCs in several new indications

Peter Senter VP, Chemistry Seattle Genetics

9.00 Arming disease-targeting antibodies with cytotoxic drugs & with cytokines• Antibody-cytokine fusions: From the bench to the clinic• Cancer cures with non-internalising antibodies• Applications of armed antibodies beyond oncology

Dario Neri Department of Chemistry & Applied BiosciencesETH Zurich

9.30 SPEED NETWORKING & MORNING REFRESHMENTS

Chair: Goncalo Bernardes Cambridge University Chair: Gail Phillips Genentech

11.00 Strategies to control stoichiometry and site of cysteine-directed antibody drug conjugation• Engineering of cysteine into antibody Fc-region to

address the challenges pertaining to classical ADCs • Obtaining antibodies with predefined sites &

stoichiometries that improve conjugation efficiency & product homogeneity

• In vitro & in vivo activity of these ideal antibody drug conjugates will be shared

Chris Lloyd Senior Scientist, Antibody Discovery & Protein Engineering MedImmune

11.30 Developing novel ADC formats to enable better ADCs• Site-specific conjugation to disulfide bonds

of antibodies & antibody fragments reduces ADC heterogeneity

• ThioBridgeTM linkers provide stable conjugates & can be used with a variety of alternative payloads using the ThioBridgeTM

George Badescu Head of Bioconjugation & Bioanalysis PolyTherics

11.00 ABT-414, an anti-EGFR ADC in patients with advanced solid tumours with amplified or overexpressed EGFR• EGFR ADCs represent an attractive therapeutic

strategy for cancer but are limited by their on-target toxicity

• ABT-414 is an ADC comprised of a unique EGFR-binding antibody (ABT-806) with tumour-specific binding properties that limit effects of the toxin on normal tissues

• ABT-414 is highly effective in both EGFR mutant & wild-type positive human tumour xenografts & Phase 1 trials are ongoing

Ed Reilly Associate Director Abbvie

11.30 Dual targeting of HER2-positive cancer with trastuzumab emtansine (T-DM1) & pertuzumab improves efficacy• Treatment of HER2-overexpressing tumour cells in vitro

with T-DM1 plus pertuzumab • Results from cell culture & mouse xenograft models

showing enhanced anti-tumour activity• In patients, this combination showed an encouraging

safety & tolerability profile with preliminary evidence of efficacy

Gail Phillips Scientist, Research Oncology Genentech

8.25 Chair’s Opening Remarks John Lambert CSO, ImmunoGen

AGENDA 18TH FEBRUARY 2014

Conference Day OneCONFERENCE OPENING & REGISTRATION



DISCOVERY STREAM: OPTIMISING LINKER AND DRUG COMPATIBILITY

DEVELOPMENT STREAM: IMPROVING PREDICTABILITY OF PRECLINICAL DEVELOPMENT

AGENDA CONFERENCE DAY ONE: 18TH FEBRUARY 2014

12.00 Novel site specific conjugation tools to improve protein drug properties • A tag & modify approach for the construction

of homogeneous modified proteins• Site-specific modification of antibody fragments with

traceless linkers

Goncalo Bernardes Department of ChemistryCambridge University

12.30 Site specific ADC generation using SMARTagTM technology• Enabling precise, & programmable, site-specific

chemical protein modification• The development of novel conjugation chemistry

resulting in ADCs with enhanced stability• Linker chemistry that optimises the potency

of the cytotoxic payload

David Rabuka CSO Redwood Bioscience (sponsored by Catalent)

12.00 Arming antibodies with an attenuated cytokine provides potent tumour cell-specific cell killing in multiple myeloma• Method whereby a cytokine is mutated to reduce

pleiotropic effects, but is also targeted by an antibody to the cancer cells, thus retaining potent anti-tumour activity

• Preclinical studies demonstrating that a CD38 antibody-attenuated IFN-alpha directs the robust tumour-killing activity to myeloma cells with minimal activity on antigen-negative cells

Sarah Pogue Director, Target Validation Teva

12.30 Bench-to-bedside translation of efficacy for ADCs using multiscale mechanistic PK/PD model• A step-by-step development of the multiscale

mechanistic model will be discussed using brentuximab vedotin as a case study

• The ability of the model to predict tumour disposition of payload & clinical outcomes such as progression free survival & complete response rates

• Answering different questions related to compound design, precision medicine & patient selection

Nahor Haddish-Berhane Senior Principal Scientist Pfizer

1.00 LUNCH & NETWORKING

2.00 Antibody-drug conjugates with novel IGN DNA alkylating agents: Design & preclinical evaluation• Selection of lead cytotoxic molecules for conjugation• Linker evaluation: Comparison of ADCs

with cleavable vs. non-cleavable linkers• Preclinical evaluation of lead ADCs: In vitro potency,

in vivo anti-tumour activity & tolerability

Ravi Chari Executive Director, Chemistry & Biochemistry ImmunoGen

2.30 Discovery of new auristatin analogues• Overview of medicinal chemistry efforts that led to the

discovery of novel auristatins as payloads for ADCs • Payload design strategies taking under consideration

physicochemical properties, ADME characteristics & the nature of the tumour physiology

Andreas Maderna Associate Research Fellow, Medicinal Chemistry Pfizer

2.00 Driving complex development of an ADC program in a global team setting to successful milestones including IND submission & Ph2 readiness milestones• Identifying & communicating potential CMC issues &

risks to the project team• Development of the analytical, outsourcing & regulatory

strategies for a challenging global supply chain

Melissa Lapierre-Devlin Senior Scientist Takeda Boston

2.30 Successfully managing product complexity in ADC process development & manufacturing• Overcoming the challenge of producing small

molecules & large molecules under GMP compliance• Supply chain & critical items to support market &

clinical trials• Considerations for scaling up process development &

final drug product form

Franck Pavan Manager, Outsourcing & Business Development Pierre Fabre

DISCOVERY STREAM: DISCOVERY & SYNTHESIS OF ALTERNATIVE ADC PAYLOADS

DEVELOPMENT STREAM: ADC PROCESS DEVELOPMENT & SCALE-UP



AGENDA CONFERENCE DAY ONE: 18TH FEBRUARY 2014

3.45 AFTERNOON REFRESHMENTS & NETWORKING

3.00 Small molecule drug conjugate (SMDC) technology: Bench to bedside applications for targeted companion imaging & therapy• Vintafolide is a potent folate-targeted conjugate that

is currently being evaluated in global Phase 3 trials• Response measurements performed with non-

invasive, real-time companion imaging agent• Application for a variety of receptor systems, and

identification of patients who would most likely benefit

Chris Leamon VP, R&D Endocyte

3.30 Homogeneous & stable ADCs by chemoenzymatic glycan remodeling-conjugation

Floris van Delft CSO Synaffix

3.00 High quality lysine-linked maytansinoid ADCs: Assays & attributes• Development of robust bioassays• Critical quality attributes & their effect on potency• Conjugates with functional activity

Gillian Payne Senior Director, BioAnalytical Science ImmunoGen

3.30 Extended Q&A with session speakers

DISCOVERY STREAM: DISCOVERY & SYNTHESIS OF ALTERNATIVE ADC PAYLOADS

DEVELOPMENT STREAM: ADC PROCESS DEVELOPMENT & SCALE-UP

PLENARY SESSION: APPROACHES FOR MAXIMISING THERAPEUTIC INDEX

4.30 Disease relevant targets for the development of next generation ADCs• Proteomic identification of targets from freshly isolated tumour samples• Generation of antibodies in the context of tumour cells• Novel chemically driven ADC platform that results in homogeneous conjugations

Thi-Sau Migone CSO Igenica

5.00 Potent novel marine derived drug payloads - A journey from initial marine findings to future prospects in ADC development• Discovering where do novel payloads come from & assessing payload

candidates with marine origin• Synthesis of those compounds & chemistry ensuring family-building

of payloads• Payload properties in vitro & in vivo will be shared as well as future prospects

for ADCs

Carmen Cuevas Director, R&D PharmaMar

5.30 Panel: Correlating ADC structure & function for optimal development• What is the right MOA for your target• Selection criteria for target, payload, linker & carrier specificity• Identifying the right lead candidate to take forward

David Stover Agensys/Astellas

Dale Ludwig Eli Lilly

Herren Wu MedImmune

After the formal presentations have finished, the networking carries on. The Drinks Reception is an informal part of the conference agenda, allowing speakers and attendees to connect with their peers after the conference in a relaxed atmosphere and continue to forge new relationships with other ADC experts.

6.15 DRINKS RECEPTION & NETWORKING



8.25 Chair’s Opening Remarks Alain Beck Head of Physico-Chemistry Pierre Fabre

AGENDA 19TH FEBRUARY 2014

Conference Day TwoCONFERENCE OPENING

PLENARY SESSION: DEFINING KEY QUALITY ATTRIBUTES FOR ADCS

8.30 Comparability study of an ADC following process change• Where are we now with our side by side studies• What are the regulators expecting to see

Stephane Cornen Head of Biochemistry & CharacterisationSanofi

9.00 Ensuring success in technology transfer of ADCs and avoiding pitfalls• Ensuring a successful transfer & reproducible conjugation process• Solid analytics, appropriate engineering design, & understanding of

process controls• Which details are critical & how do they get effectively communicated

between sites or companies?

Cynthia Wooge Global Strategic Marketing SAFC

9.30 State-of-the art mass spectrometry structural characterisation of ADCs • Extending the use of native mass spectrometry • Comparison to orthogonal analytical methods • Optimising sample preparation • Understanding pharmacokinetic & catabolic pathways

Alain BeckHead of Physico-ChemistryPierre Fabre

10.00 Benefits of characterising ADC therapeutics using enzyme-facilitated approach

Fredrik OlssonCOO Genovis

10.15 MORNING REFRESHMENTS & NETWORKING

DEVELOPMENT STREAM: TESTING & IMPROVING PRODUCT QUALITY

Chair: Andrew Theobald GSK Chair: Alain Beck Pierre Fabre

10.45 Application of bispecific antibody technologies to achieve ADC functionalities• Bispecific targeting vehicles in different formats for capture

& delivery of haptenylated payloads• Ensuring defined composition of vehicle-payload complexes• Targeted delivery of cytotoxins

Ulrich Brinkmann Scientific Director Roche

11.15 The challenge of ADC target identification & validation• Target selection/prioritisation process• Validation of differential protein expression &

internalisation properties• Cell killing with experimental ADC

Patrick Vincent Head, TCAL Oncology Research Takeda San Diego

10.45 Investigation into temperature-induced aggregation of an antibody drug conjugate• Exploring the effect of conjugation on the antibody

conformational structure • Profiling the effect of thermal stress on the physical

stability, specifically aggregation, of ADCs• Develop mechanistic understanding of ADC

aggregation & discuss practical implications

Nia Beckley Senior Research Associate Genentech

11.15 Planning & implementing strategies for ADC CMC development projects• Establishing an efficient supply chain for ADC products• Identifying critical processes for ADCs• Managing the interface between the small molecule &

biologics CMOs

Pernille Høyrup Hemmingsen CMC Project Manager Genmab

DISCOVERY STREAM: IDENTIFYING THE RIGHT TARGETS FOR THE RIGHT CARRIERS



DEVELOPMENT STREAM: TESTING & IMPROVING PRODUCT QUALITY

11.45 Panel: Leveraging knowledge of cellular biology to improve ADC targeting• Exploitation of trafficking mechanisms• Potential for targeting tumour specific antigens• Overcoming the challenges of antigen shedding &

differential tissue expression • Potential for dually targeted antibody carriers

Alexey Lugovskoy Merrimack Patrick Vincent Takeda San Diego David Satijn Genmab

11.45 Dealing with the challenge of ADC drug product formulation• Early pipeline developability assessments• Ensuring a stable formulation in a back loaded

development process

Stefan Bracht Director, Formulation Development Bayer

DISCOVERY STREAM: IDENTIFYING THE RIGHT TARGETS FOR THE RIGHT CARRIERS

AGENDA CONFERENCE DAY TWO: 19TH FEBRUARY 2014

12.15 LUNCH & NETWORKING

2.00 A cytolytic Fusion Protein (cFP) based on a de-immunised variant of Pseudomonas exotoxin is well tolerated & potently shrinks tumour xenografts• Overcoming traditional limitations of immunogenicity &

off-target toxicity, particularly vascular leak syndrome• Development de-immunised format that has reduced

off-target toxicity, & retains high therapeutic potency in multiple xenograft models

Gerhard Niederfellner Head, Tumour Biology, pRED Roche

2.30 Antibody–drug conjugates: Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles• Novel construct design to deliver high volumes of

cisplatin with targeting specificity• Results from testing in melanoma & carcinoma

mouse xenografts• Improvements to the therapeutic index of antiblastic

therapy in advanced melanoma which is refractory to chemotherapy

Patrizio Giacomini Immunology Lab Istituto Nazionale Tumori

3.00 Experimental treatment of bladder cancer with α-emitter (Bi-213) immunoconjugates targeting EGFR • High efficiency demonstrated due to induction of

DNA double-strand breaks independent of cellular oxygenation

• Potential applications in hypoxic tumours will also be explained

Christof Seidl Department of Nuclear MedicineTechnische Universität München

2.00 Achieving proof-of-concept for Centyrin-drug conjugates• Designing Centyrins, novel consensus FN3 domains

which have novel properties• Demonstrating excellent biophysical properties,

ideal for conjugation technologies• Preparation & validation of proof-of-concept of

Centyrin-drug conjugates

Shalom Goldberg Research ScientistJohnson & Johnson

2.30 BT-062: Tackling the challenge of targeting CD138-positive malignancies• Clinical data from two monotherapy studies using

different treatment schedules of BT-062 in multiple myeloma will be summarised

• Safety & efficacy data of BT-062 in combination with Lenalidomide & Dexamethasone will be presented

• Rationale for expanding clinical development of BT-062 into solid tumour indications will be discussed

Thomas Haeder Manager, Corporate Clinical Research Biotest

3.00 Extended Q&A with session speakers

DEVELOPMENT STREAM: DEVELOPING ANTIBODY DRUG CONJUGATES TOWARDS IN HUMAN TRIALS

DISCOVERY STREAM: XDCS & FORMATS OF THE FUTURE

3.30 AFTERNOON REFRESHMENTS & NETWORKING



AGENDA CONFERENCE DAY TWO: 19TH FEBRUARY 2014 PLENARY SESSION: CLINICAL CONSIDERATIONS FOR THE SUCCESS OF ADCS

4.00 Optimising ADC clinical trial design in to demonstrate optimal benefit• Understanding the mechanistic considerations for ADCs• Deciding on the optimal endpoints• Successfully monitoring response & toxicity

Rebecca KristeleitSenior Lecturer & Honorary Consultant, Early Phase Clinical Studies UCL

4.30 Lessons learned from progressing maytansinoid antibody-drug conjugates (MAY-ADCs) through clinical development• The success of T-DM1 (Kadcyla) shows the promise of MAY-ADC technology

for solid tumours• Update on findings with other MAY-ADCs in clinic today• Learnings from clinical findings applied to the discovery & development of ADCs

John Lambert CSO ImmunoGen

5.00 CHAIR’S CLOSING REMARKS

Media Partners

A thoroughly engaging and intellectually stimulating experience, World ADC has been packed with new ideas, techniques & friends. The possibilities for new breakthroughs and collaborations based on my time here has made it even more motivating to get back to the lab.

Tweet your thoughts with #WorldADC and @world_adc

Connect with 2500+ ADC enthusiasts on Linkedin. Search groups for Antibody Drug Conjugates



PRE-CONFERENCE WORKSHOPS 17TH FEBRUARY 2014:

Workshop A Nonclinical bioanalytical & safety development of ADCsTime: 9.00am - 12.00pm

Workshop BTroubleshooting and engineering of antibody constructs Time: 9.00am - 12.00pm

For recombinant antibodies and their derivatives we have shown that poor stability of individual variable domains is not only limiting the biophysical properties of small antibody fragments, but also affects the production yield, stability and homogeneity of full length IgGs containing these domains.

Attend this workshop to:• Recognise potentially troublesome antibody variable

domain sequences• Use structure-based protein engineering to optimise

the biophysical properties of your antibody while retaining its affinity and specificity

• Master strategies to improve the biophysical properties of these domains by a limited number of point mutation when working with human or humanised sequences

• Know how to choose the appropriate framework to compensate for problems in the original sequence and improve stability while humanising non-human antibodies

• Optimise your choices of the best possible format for your antibody

Attend this workshop to ultimately improve your expression strategies for both full-length antibodies and other immunoglobulin based products.

Workshop Leaders: Jonas Schaefer & Annemarie Honegger University of Zurich

Workshop Leaders: Peter Bach BioPharmaLogic

This workshop will focus on the nonclinical bioanalytical methods that need to be developed and put in place to ensure that meaningful nonclinical safety studies can be undertaken. Safety data from these GLP studies can be translated into relevant information for selecting of starting dose, patient exclusions and the clinical risk evaluation and management strategy (REMS).

The workshop will allow you to:• Evaluate target risks and manage these through

the nonclinical and clinical development• Understand the need to develop robust and sensitive

bioanalytical methods and undertake biomarker selection to support nonclinical & clinical development

• Ensure that the maximum amount of safety information will be generated to facilitate a robust IND submission with valid patient risk assessment and REMS for the first human doses

• Interact with regulatory agencies to facilitate their early input to early development programmes.

Please note you can either attend Workshop A or B in the morning and either Workshop C or D in the afternoon.OR

Workshop CEstablishing a harmonised ADC manufacturing supply chainTime: 1.00pm - 4.00pm

Workshop Leader: Iwan Bertholjotti Lonza

Decisions must be made early on in consideration of how to source different components of the ADC supply chain in an environment of limited capacity for manufacturing of cytotoxic biologics.

In this workshop:• Define and discuss the critical supply chain

management issues that are important for clinical and commercial supply of ADCs

• Find out the best approaches to cytotoxic payload/ linker development and manufacturing, and explore the safety and EH&S requirements

• Understand how to avoid the pitfalls associated with ADC process development and manufacturing

• Achieve efficient cell culture process development and antibody manufacturing and control product quality and process consistency

There will be focus on each step of the manufacturing supply chain with specific discussion around technology transfer, analytical method development and validation, regulatory affairs and approval strategy, and timeline harmonisation.



Workshop DOptimising payload delivery through selection of the right carrierTime: 1.00pm - 4.00pm

Workshop EImproving clinical relevance during cancer drug discovery through incorporation of aspects of the tumour microenvironment and application of imaging technologies in preclinical modelsTime: 8.00am - 11.00am

Workshop FImaging masterclass on in vivo molecular imaging as a route to more effective therapiesTime: 11.30am - 2.30pm

Workshop Leader: David Bramhill Bramhill Biological Consulting

Workshop Leader: Anna Grabowska University of Nottingham

Workshop Leader: Laura Melendez-Alafort University of Padua

Alongside full length IgGs antibody fragments, domains and even smaller “scaffolds” are now being explored for targeted payload delivery. This workshop covers the key considerations for using engineering novel scaffolds and other antibody formats for binding to diverse targets. What can be transferred from our knowledge of antibody targeted drug conjugates, and what new aspects need to be considered or re-thought for small scaffolds?

In this workshop:• Assess the pros and cons of scaffolds versus full

length antibodies and how they can be engineering to optimise target binding

• Debate which formats will be most successful in a series of practical cases studies designed to aid selection of format based on different target biologies

• Consider how additional biophysical characteristics of the carrier can influence selection such as PK, penetration and stability

POST-CONFERENCE WORKSHOPS 20TH FEBRUARY 2014:

A high proportion of anti-cancer drugs fail at the early clinical trial stage in spite of showing promise in preclinical cancer models. This suggests that current models do not reflect the situation in the patient. This workshop will focus on aspects of the tumour microenvironment (TME) that influence drug sensitivity and tumour development, which may be missing or poorly-represented in preclinical models.

At this workshop participants will:• Identify aspects of the TME that may influence tumour

progression and cancer drug responsiveness• Consider how imaging technologies can be used

to interrogate current preclinical cancer models to assess their clinical relevance and monitor the influence of the TME on drug response

• Discuss approaches for incorporating elements of the TME & imaging technologies to challenge new drugs & drug combinations in a more clinically-relevant setting

You will leave with the ability to select the most appropriate models for preclinical target identification and validation, and pipeline development, with the ultimate aim of improving success in the clinical phase.

Molecular imaging is a complex of imaging modalities that performs a non-invasive monitoring of spatial-temporal distribution of molecular or cellular processes and may be used for real-time monitoring of antibody-drug conjugates as well as for early detection of their therapeutic responses and drug efficacy.

This workshop will allow you to:• Find the potential that molecular imaging offers in the

diagnostic management of diseases & drug discovery, by means of tracking biochemical processes in vivo

• Discover the most important molecular imaging strategies to perform in vivo imaging such as radionuclide imaging (PET & SPECT), bioluminescence

& fluorescence imaging, & nano-platforms for molecular imaging e.g. nanoparticles & quantum dots

• Appreciate the strengths and weaknesses of the molecular imaging modalities

• Learn about the combination of the molecular imaging modalities approach which exploits the strengths of individual modalities and overcomes their limitations

Please note you can either attend Workshop A or B in the morning and either Workshop C or D in the afternoon.OR



OUR SPONSORS:

Why Sponsor?Sponsoring or exhibiting at World ADC represents an industry-leading opportunity to access key decision makers within both established and emerging ADC companies. High growth, high potential markets like ADCs become crowded very quickly so make sure you seize your chance now.

For more information on sponsorship, Please Contact Miles Harley by email: [email protected] or call +44 (0) 20 3141 8700

OUR PARTNERS

Thank you for another fantastic conference. I am confident that we’ve achieved what we set out to achieve and we feel the conference was a great success for PolyTherics.

Exhibitors Spotlight Partners



TERMS & CONDITIONS

Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes.

Full payment is due on registration.

If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

To register, simply Tel: +44 (0)203 141 8700 Fax: +44 (0) 20 7222 2685 Email: [email protected] Send this form to us and we’ll issue an invoice for payment. Alternatively, register online here: www.adcsummit-europe.com/register

Significant discounts are available for not for profit organisation. Please email [email protected] for more information.

10% Discount – 3 Delegates15% Discount – 4 Delegates20% Discount – 5 or more Delegates

Register & Pay before 8th November

Register & Pay before 13th December

Register & Pay before 10th January Standard Prices

Gold Package 2 day conference + 2 additional days 4095 (save 700) 4195 (save 600) 4295 (save 500) 4395 (save 400)

Silver Package 2 day conference + 1 additional day 3097 (save 500) 3197 (save 400) 3297 (save 300) 3397 (save 200)

Bronze Package 2 day conference only 2099 (save 300) 2199 (save 200) 2299 (save 100) 2399

EVENT PRICES ALL PRICES ARE PLUS VAT (CHARGED AT 19%)

NOT FOR PROFIT ORGANISATION DISCOUNTS

TEAM DISCOUNTS

REGISTRATION DETAILS

Purchasing workshops individually is possible. Please contact us for more details

PRICING & REGISTRATION

Conference & Workshops

VENUE AND ACCOMMODATION

Maritim Kurhaushotel Bad Homburg Ludwigstraße 361348 Bad Homburg v. d. H. Germany

http://www.maritim.com/en/hotels/germany/kurhaushotel-bad-homburg

Not far from Frankfurt, the elegant spa city of Bad Homburg enjoys enviable access to the airport, the central train station and the exhibition grounds. Located right in the heart of town adjacent the spa parklands and the picturesque pedestrian zone, the Maritim Kurhaushotel was completely renovated in 2013 to now greet its guests in all new splendour.


17 - 20 february 2014 frankfurt, germany - cipf · 17th - 20th february 2014 frankfurt, germany...

Documents